Vaxcyte, Inc.
PCVX
Clasificación en acciones
#2074
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Precio por acción
$63.69
Capitalización bursátil
$10.02B
Cambio (1 día)
-3.84%
Cambio (1 año)
50.39%
País
US
Comercio Vaxcyte, Inc. (PCVX)
Categoría
Healthcare
Historial del precio de la acción de Vaxcyte, Inc. (PCVX)
Precio más alto de cierre: $65.60 el 2026-10-01
Precio más bajo de cierre: $32.16 el 2020-06-01
Precio más bajo de cierre: $32.16 el 2020-06-01
Historial del precio de la acción de Vaxcyte, Inc. desde 2020 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | 18.84% |
| 2025 | -48.18% |
| 2024 | 49.19% |
| 2023 | 30.50% |
| 2022 | 103.95% |
| 2021 | -26.14% |
| 2020 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $520.06 | 22.00% |
US
|
|
| $249.65 | 808.13% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $887.09 | 6.27% |
NL
|
|
| $752.87 | 7.40% |
CH
|
